On June 22, 2026, China’s National Medical Products Administration approved satricabtagene autoleucel (satri-cel, CT041) from CARsgen Therapeutics for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma after at least two prior lines of therapy. It is the first CAR T-cell therapy approved anywhere for a solid tumor. Nine years after the first CAR-T approval, all seven products on the US market treat blood cancers, while solid tumors account for roughly 90% of cancer cases.
Why CAR-T Transformed Leukemia and Lymphoma
CD19 is close to an ideal target: uniformly expressed on B-cell malignancies, absent outside the B-cell lineage, and its predictable on-target toxicity, B-cell aplasia, is survivable with immunoglobulin replacement. The tumor also sits where infused T cells already circulate, with no stroma to cross and no hostile microenvironment to survive.
The durability followed. In the five-year ZUMA-1 analysis, axicabtagene ciloleucel produced an 83% objective response rate (58% complete responses) in refractory large B-cell lymphoma, with a five-year overall survival rate of 42.6% (95% CI, 32.8–51.9). Two chronic lymphocytic leukemia patients treated at Penn in 2010 remained in remission more than a decade later, with CAR T cells still detectable.
Why Solid Tumors Remain Difficult
Four barriers compound one another. There is no CD19 equivalent, nearly every solid tumor antigen is also expressed in normal tissue, and the window can be lethal, as in the 2010 NCI case of a patient who died five days after HER2-directed CAR-T recognized low-level HER2 on lung epithelium. The cells must then cross aberrant vasculature and dense matrix to reach the tumor. Once there, TGF-β, hypoxia, regulatory T cells, and myeloid-derived suppressor cells actively disarm them. Finally, antigen expression is heterogeneous, giving antigen-negative clones a straightforward escape route while chronic stimulation drives exhaustion.
The First Crack: CT041-ST-01
Satri-cel’s approval rests on the first randomized controlled trial of CAR-T in solid tumors, published in The Lancet in 2025. Across 24 Chinese sites, 156 patients refractory to at least two prior lines were randomly assigned 2:1 to satri-cel (n=104) or treatment of physician’s choice (TPC; n=52).
Median progression-free survival was 3.25 months (95% CI, 2.86–4.53) versus 1.77 months (95% CI, 1.61–2.04) with TPC (HR, 0.37; 95% CI, 0.24–0.56; one-sided P < .0001). Median overall survival was 7.92 months versus 5.49 months (HR, 0.693; 95% CI, 0.457–1.051; one-sided P = .0416). Confirmed objective response rate was 22% versus 4%.
The result deserves reading in both directions. It is a genuine randomized win where no options existed, and the gains are measured in weeks, only one in five patients responded, and 16 of 104 patients randomized to satri-cel never received it. Grade 3 or higher treatment-emergent adverse events occurred in 99% of treated patients; cytokine release syndrome occurred in 95%, almost entirely grade 1–2, with no ICANS in either arm.
Armored CAR-T
Armoring adds payloads so the cell can modify its environment rather than merely survive it. The clearest proof came in lymphoma: huCART19-IL18, engineered to secrete interleukin-18, produced an 81% response rate (52% complete) in 21 patients who had already progressed after commercial CD19 CAR-T (NEJM, 2025). In solid tumors the dominant payload is a dominant-negative TGF-β receptor, tested first in prostate cancer and now in Legend Biotech’s DLL3-targeted LB2102, which reported a 28.6% objective response rate and 78.6% disease control rate at higher doses in small cell lung cancer at ASCO 2026.
Logic-Gated CAR-T
If no antigen is clean enough alone, the cell can be made to evaluate two signals. A2 Biotherapeutics‘ Tmod platform pairs an activator receptor against mesothelin with a blocker receptor recognizing HLA-A*02, exploiting tumor-specific loss of heterozygosity rather than a difference in expression level. At SITC 2025, the EVEREST-2 study reported data on the first nine patients, including what the company describes as the first complete response to a CAR T-cell therapy in non-small cell lung cancer. ArsenalBio‘s AB-1015 takes the AND-gate route in ovarian cancer, using an ALPG/P priming receptor to induce a mesothelin CAR. The trade-off is population size: requiring two conditions narrows eligibility sharply.
In Vivo CAR-T Manufacturing
Autologous CAR-T requires apheresis, centralized manufacturing, lymphodepletion, and weeks of vein-to-vein time, with total cost of care that can exceed $1 million. In vivo approaches generate the cell inside the patient, using either lipid nanoparticles carrying CAR mRNA or engineered lentiviral particles. At ASCO 2026, Kelonia‘s anti-BCMA KLN-1010 reported 18 patients dosed with a 100% response rate and MRD-negative marrow at one month in all evaluable patients, without lymphodepleting chemotherapy, with a 13-day median time from consent to infusion, and with outpatient dosing approved.
The capital has followed: AstraZeneca acquired EsoBiotec for up to $1 billion, AbbVie acquired Capstan for up to $2.1 billion, Kite bought Interius for $350 million, and Eli Lilly agreed to acquire Kelonia for up to $7 billion. But every in vivo program with human data targets CD19 or BCMA. The approach solves manufacturing and access, not trafficking, heterogeneity, or the microenvironment.
Key Takeaway
Satri-cel establishes that CAR-T can produce a randomized survival signal in a solid tumor and reach a market. It does not establish that CAR-T will do to gastric cancer what it did to lymphoma. Solid tumor CAR-T has moved from “does not work” to “works modestly, in selected patients, with substantial toxicity”, roughly where CD19 CAR-T stood in 2013.
The programs worth watching are those stacking these strategies, and the likeliest near-term inflection may not be a new target but a new position in the treatment algorithm. CARsgen is now testing satri-cel in the adjuvant setting and sequentially after first-line therapy, on the hypothesis that engineered T cells underperform partly because they are given last, to patients whose immune systems are already exhausted.
Read more insight regarding CAR-T on OncoDaily.